Xcout Intel
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Subscribe to see Olema Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Olema Pharmaceuticals, Inc. at a glance
Olema Pharmaceuticals, Inc. is a biotechnology company headquartered in San Francisco, United States. It is publicly listed (OLMA) with a market capitalisation of $683.1M. Xcout tracks 73 named people at Olema Pharmaceuticals, Inc., including Sean Bohen (President, Chief Executive Officer & Director). Xcout recorded 45 job postings from Olema Pharmaceuticals, Inc. in the last 90 days.
Olema Pharmaceuticals, Inc. leadership
- Sean BohenPresident, Chief Executive Officer & Director
- Sean P. Bohen, M.D., Ph.D.President and CEO
- Jason O'ByrneCFO, Principal Financial Officer & Accounting Officer
- Naseem ZojwallaChief Medical Officer
- Shawnte MitchellChief Legal Officer & Corporate Secretary
- David C. MylesChief Scientific Officer
67 more named people on record for Olema Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Olema Pharmaceuticals, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $87.4M | 8 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Olema Pharmaceuticals, Inc.
Xcout recorded 45 job postings from Olema Pharmaceuticals, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Olema Pharmaceuticals, Inc.'s hiring signals →
Hiring vs the trend
Based on 32 job postings in the last 8 weeks (17 Aug – 11 Oct 2026), compared with 181 scale-up healthcare companies.
This describes a hiring pattern — how often Olema Pharmaceuticals, Inc.’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Investors
Olema Pharmaceuticals, Inc. competitors
A few of Olema Pharmaceuticals, Inc.'s closest competitors — see the full list of competitors and alternatives →
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Asieris Pharmaceuticals is a global innovative biopharmaceutical company founded in March 2010 that specializes in the development of treatments for genitourinary tumors and women's health.
Oriva Therapeutics is a biotechnology and pharmaceutical company headquartered in Barcelona, Spain. The venture is dedicated to advancing innovative and disease-modifying approaches to improve clinical outcomes for chronic women's health conditions.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Oviva Therapeutics is a biotechnology research subsidiary headquartered in New York, NY, focused on women's health. The company develops novel therapeutics designed to target ovarian function and extend healthspan.
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Get Olema Pharmaceuticals, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Olema Pharmaceuticals, Inc. in Xcout Intel
- 73 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access